Opinion
Video
Future Perspectives on the Treatment of NSCLC
Author(s):
Dr Edgardo Santos highlights key takeaways from the presented data and provides insights into how these findings could shape the future landscape of healthcare directions.
This is a video synopsis/ summary of an OncLive Insights® featuring Edgardo S. Santos, MD, FACP, FCCP.
In conclusion, Santos summarized key lung cancer advances from the 2023 World Conference on Lung Cancer and the European Society of Medical Oncology Congress. He covered data on new targeted therapies such as the HER2 antibody-drug conjugate trastuzumab deruxtecan and datopotamab deruxtecan for molecularly selected patients with non–small cell lung cancer. Beyond targets, combination approaches are ongoing, including antibody-drug conjugates with immunotherapy. However, developing effective regimens for immunotherapy-refractory lung cancer remains an unmet need. Santos expressed optimism that new treatment options are on the horizon for patients with lung cancer, both with and without targetable genomic alterations.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
